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Objective: The treatment of patients with cancer has advanced into a complex, multi-
modal approach incorporating surgery, radiation, and chemotherapy. Managing wounds
in this population is complicated by tumor biology, the patient’s disease state, and ad-
ditional comorbidities, some of which may be iatrogenic. Radiation therapy, frequently
employed for local-regional control of disease following surgical resection, has quantifi-
ablenegativehealingeffectsduetolocaltissuefibrosisandvasculareffects.Chemother-
apeutic agents, either administered alone or as combination therapy with surgery and
radiation,mayhavedetrimentaleffectsontherapidlydividingtissuesofhealingwounds.
Overall nutritional status, often diminished in patients with cancer, is an important as-
pecttotheabilityofpatientstohealaftersurgicalproceduresand/ortreatmentregimens.
Methods: An extensive literature search was performed to gather pertinent information
on the topic of wound healing in patients with cancer. The effects that surgical proce-
dures, radiation therapy, chemotherapy, and nutritional deficits play in wound healing in
thesepatientswerereviewedandcollated.Results:Thecurrentknowledgeandtreatment
of these aspects of wound healing in cancer patients are discussed, and observations and
recommendations for optimal wound healing results are considered. Conclusion: Al-
though wound healing may proceed in a relatively unimpeded manner for many patients
with cancer, there is a potential for wound failure due to the nature and effects of the
oncologic disease process and its treatments.
The physiologic changes that patients with cancer undergo as a part of the disease pro-
cess itself, or in the course of treatment and recovery, are substantial and impact all aspects
of their lives. With current treatment strategies aimed at multimodal protocols including
surgery, radiation, and chemotherapeutic regimens, it is not surprising that wound healing
becomesamatterofcriticalimportance,regardlessofwhetherthewoundwassurgicallycre-
ated,acomplicationofradio-orchemotherapy,orduetodiseaseprogression.Manypatients
undergo some form of surgical procedure during the course of their disease for diagnostic
or staging purposes, treatment, or to manage complications of other treatment regimens.1
While the majority of wound healing is host-mediated, surgeons have the responsibility to
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provide wounds with a biologically favorable environment to facilitate wound healing and
consequently should be aware of the many factors that interact in the healing of wounds,
especially in patients with cancer.2
Wound healing is an orderly progression of carefully regulated, complex, interrelated
processes that result in anatomic and functional integrity of tissues. Any processes, treat-
ments, or interventions that modify or disrupt this progression can interfere with wound
healing. Treating patients with cancer involves multiple modalities, all of which impact
their ability to heal wounds. Surgery is often employed for curative purposes either by erad-
icating the tumor or by debulking tumor in anticipation of further treatment. Consequently,
the timing of surgical intervention in relation to radio- or chemotherapy as well as the pa-
tient’snutritionalstatusisfundamentallyimportantinrecoveryfromproceduresandwound
healing in general. Radiotherapy has a significant role in local control of disease or in the
treatment of radiosensitive tumors; however, because it nonspecifically damages adjacent
tissue in addition to cancer cells, it can further complicate wound healing. Chemothera-
peutic regimens are frequently used as monotherapy or in conjunction with surgery and
radiation in the treatment of cancer. These pharmacologic agents target proliferating cells,
and can be used at any point in the treatment program—preoperatively, during the surgical
procedureitself,orpostoperativelyaswell.Theultimategoalofthismultimodalapproachto
treating cancer is to eradicate disease while causing the least amount of harm to the patient;
unfortunately, injury to the patient does occur, and the degree of damage to surrounding
tissues impacts overall wound healing.
Consequently, it is crucial that physicians coordinate their treatment regimens to help
optimize wound healing by understanding the effects of radiation, chemotherapy, and nu-
trition on wound healing in patients with cancer.
RADIOTHERAPY
Radiation as a treatment modality is based on the ability of target tissues to absorb energy,
which on the atomic scale causes excitation or “ionization” of electrons to higher energy
orbits around the nucleus. Energy is released when these electrons return to their previous,
more stable orbits, resulting in cellular damage to vital structures including DNA. The
amount of radiation delivered to tissues is quantified in radiation absorbed doses (rad) or
gray (Gy), with one Gy equivalent to 100 rad. Although the total dose of ionizing radiation
administered in clinical settings is individualized on the basis of patient size and purpose,
the amount of radiation can range from 0.25 millirad for a chest radiograph, to treatment
dosesof4500radinradiationoncology,tonear-tolerancedosesof7500radinbonemarrow
ablation procedures.
The biologic effect of radiation on tissues has been recorded as early as the 1890s,
with its application in the treatment of cancer being described shortly thereafter. It was
observed in 1906 that ionizing radiation was cytotoxic to the germinal cells of the testis
while the mature Sertoli cells were left relatively undamaged.3 This ultimately led to the
conclusionthattheeffectsofradiationweremorefocusedondividingcells,whichthenwas
applied in the 1920s as a viable treatment option for cancer.4,5 However, the detrimental
effect of ionizing radiation on healthy tissue was also becoming apparent, with the classic
description of localized erythema and slow to heal skin ulcerations being reported.6
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Multiple factors are involved in determining the cumulative effects of radiation on
tissue: the total dose and duration of exposure, the oxygenation status of the tissue, and the
positionofthecellswithinthecellcycleareimportantconsiderations.Radiationexposureis
adose-dependenteffect,withimprovedsurvivaloftissueswithloweramountsofexposure.7
Coutard demonstrated in 1934 that smaller, more frequent doses of radiation were more
toxic to cancer cells with less damage to surrounding tissues than one large, single dose.5,8
Thisfactformsthebasisforcurrentprotocolsinradiationoncology,inwhichthecumulative
dose is fractionated and protracted over a period of time to minimize overall toxicity. Most
therapeutic radiation is given in 20 to 30 fractions of 200 to 300 rads, limited to cumulative
doses of 6000 rads or less, over a 5- to 6-week period. Tissue oxygenation and perfusion is
also important: hypoxic tissue is more radioresistant than vascularized tissue.9 On a similar
note, actively dividing tissues are more susceptible to damage than resting cells: cells in the
G2-M phases of the cell cycle are the most sensitive to radiation damage, while cells in the
Sphasearetheleastsensitive.10,11 Intumorbiology,thisobservationisclinicallysignificant,
as rapidly dividing cancer cells will be more susceptible to radiation-induced cell damage;
however, healthy tissues with high turnover rates such as epithelium or mucosa will also be
injured, which ultimately can lead to delayed healing.
External beam radiation is the most commonly used modality in radiotherapy for can-
cer. The radiation beam is by necessity delivered through the skin and underlying structures
before reaching its target tissue. Unfortunately, this results in unwanted radiation damage
to the surrounding tissues along with the target tissue, resulting in early skin changes fol-
lowed by chronic, progressive damage occurring more than 6 months after therapy has been
completed. Acute findings are typically reversible and correlate with the total dose and
frequency of radiation treatments: findings include erythema, dry desquamation followed
by wet desquamation, ultimately progressing to skin necrosis.6 The early response to ra-
diation is an inflammatory reaction with erythema, swelling, warmth, and tenderness; at
doses greater than 4000 rads, moist desquamation with bullae and ulceration is sometimes
seen.12 These ulcers typically heal after the conclusion of the treatment. Delayed or chronic
effects are seen at approximately 6 months after radiation therapy, and can include changes
inskinpigmentation,increasingfibrosis,sebaceousglanddysfunction,lossofhairfollicles,
telangiectasia of capillary beds, skin necrosis, and even tumor genesis.6,13 These chronic
changes are usually irreversible.
Radiation-induced skin changes are the most visible effects on irradiated tissues. One
ofthefirstchangesseenisdrynesswithintheirradiatedarea.Oncethesquamousepithelium
of the skin is damaged, the tissue sloughs off in either a dry or moist desquamation. Cell
sloughing occurs within weeks after exposure due to the continued maturation of squamous
cells without further cell division14; the rate of sloughing is dependent on the turnover
of these growth-arrested cells. Different species have been demonstrated to slough skin
cells at different rates: in humans, the turnover time for the epidermis ranges between 59
and 72 days.15,16 This process ultimately results in a thin, translucent appearance to the
skin,absenthairfolliclesandsebaceousglands,andirregularpigmentationduetodamaged
melanocytes. The hypoxic, thin, dry epidermis also has lower tensile strength, making it
susceptible to microscopic and macroscopic tears, which can lead to infection or chronic
ulceration. This process further delays wound healing in irradiated tissues.6,14
In addition to skin structure changes, the underlying connective tissue also displays
histologic changes in response to ionizing radiation. Acute changes in connective tissue
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include inflammation and edema of collagen bundles17 with deposition of a fibrinous ex-
udate below the epidermis. This is followed by gradual replacement of adipose tissue and
extracellular matrix by dense fibrous tissue and atypical fibroblasts.14 These cells do not
proliferateaswellashealthyfibroblasts,anddepositanimmaturecollagensubtype.Evenat
time periods of 15 to 20 years following radiation exposure, fibroblasts have been found to
contain intracellular structures such as degenerating mitochondria, multiple vacuoles, and
irregular rough endoplasmic reticulum that indicate permanent damage.18 Clinically, this is
evidenced by decreased wound tensile strength in comparison with controls, which further
delays wound healing following radiotherapy.19
Radiation exposure has a detrimental effect on vascular structures as well. After
exposure to ionizing radiation, superficial blood vessels initially dilate, resulting in ery-
thematous skin changes. The arteries and arterioles within the irradiated tissue undergo
loss of elasticity and progressive vascular sclerosis, resulting in chronic tissue hypoxia.20
Microscopically, the lumens of these vessels occlude with fibrin thrombi, leading to tis-
sue edema. This loss of vascular supply continues to progress in a near linear fashion
for the remainder of the patient’s life, leading to long-term, localized deficits in wound
healing in these patients.21,22 While most authors suggest that progressive microvascu-
lar occlusion is the primary cause of poor wound healing in irradiated tissues, others
have suggested that damage to the basal layer of the epidermis may play a major role
in chronic radiation damage.18 Another possibility is that radiation may have direct effects
on other components of the wound, such as collagen, with vascular damage as a secondary
occurrence.15,18,19
The complications of wound healing are worsened by radiation exposure to skin, con-
nective tissue, and underlying vasculature. Clinically, prior radiation exposure has been
demonstrated to increase the incidence of flap failures, fistulas, wound necrosis, delayed or
prolonged healing, infection, and exposure of vital structures.23−26 Of note, wound healing
is most affected by ionizing radiation when surgery is performed 6 months or more after
radiation therapy. During the intervening period, the irradiated tissue becomes hypoxic, and
fibroblasts become dysfunctional, which can lead to increased wound healing complica-
tions. Consequently, the timing of surgery in reference to proposed radiotherapy can have
a significant impact on the outcome of wounds.26−28
Preoperative radiotherapy prior to surgical resection or tumor debulking is based on
several tenets of tumor biology. Proponents suggest that manipulation of the tumor during
surgical exploration may promote metastatic disease by “spillage” of viable cancer cells
intotheoperativesiteorvasculature,leadingtorecurrenceordissemination.29 Preoperative
radiation therapy may decrease the viability of tumor cells, making them less likely to
survive or proliferate on spillage.5,30 However, this has not been definitively demonstrated:
arandomizedstudyinvolvingpreoperativeversuspostoperativeradiationtherapyonpatients
with head and neck cancer did not yield clinically significant improvement in outcomes.28
Another indication for preoperative radiation may be to decrease the overall tumor volume
prior to surgical exploration, thus potentially allowing for total excision of a previously
unresectable lesion. One caveat of this theory is that the volume of tissue excised in the
surgical specimen may actually be higher following preoperative radiotherapy, due to the
extensive scarring and fibrosis seen in tissues following radiation treatment.24,31 Also, a
preoperative reduction in tumor volume locally may not necessarily correlate with a higher
cure rate postoperatively.32
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The effects of radiation on wound healing are primarily contingent on the total amount
of radiation exposure as well as the timing and overall duration of treatment. Preoperative
radiotherapy typically occurs 3 to 6 weeks prior to surgery. When doses larger than 50 Gy
are administered, or treatments are given less than 3 weeks before surgery, a significant
increase in wound complications results.14,26,29,33,34 In these situations, even the transfer
of healthy tissue from outside of the irradiated field results in delayed wound healing in
comparison with flap healing when postoperative radiotherapy is utilized.35
Fewer wound complications have been demonstrated when postoperative radiation
therapy is selected.6 Because acute radiation exposure delays wound healing due to effects
on the skin, connective tissue, and vasculature, it is logical to conclude that the effects on
healing wounds can be minimized if the majority of wound healing has occurred prior to
radiationtreatment.If,however,woundhealingisincompleteorthewoundisinfectedwhen
radiation therapy is initiated, further complications may arise. Although 3 weeks postop-
eratively has been deemed sufficient time for wound healing to progress prior to starting
radiotherapy, this may be delayed by up to several weeks to allow for infection to resolve
or complete but delayed healing to occur.14,36 Treatments should be initiated within 6 to
8 weeks postoperatively, as the benefits of radiotherapy may decrease if treatments are
delayed further.37,38 Interestingly, Isaacs et al demonstrated that radiation therapy could
be initiated in open wounds if “appropriate precaution” is taken.38 This includes ensuring
adequate nutritional support and starting radiotherapy to surrounding tissues, preferably
before 6 weeks have elapsed postoperatively.38 This concept challenges the principle of al-
lowing wounds to completely heal before initiating radiotherapy in order to prevent further
delay in necessary treatments. If local recurrence rates are similar in cases of preoperative
versus postoperative radiation therapy in overall cancer treatment, it is preferable to per-
form radiotherapy postoperatively to minimize wound healing complications in this patient
population.
CHEMOTHERAPY
Chemotherapy, acting alone or in conjunction with surgery and radiation, is a fundamental
treatment of cancer. This treatment modality targets proliferating cells by interfering with
specific components of the cell cycle. When used in combination with surgery, chemother-
apeuticregimensmaybeindicatedpreoperativelytodecreasethetumorburdenpriortosur-
gical resection, or postoperatively to help eradicate residual disease. Although chemothera-
peutic agents preferentially target rapidly dividing cells, any tissue can be affected by these
treatments: macrophages and fibroblasts involved in wound healing are just as susceptible
to these effects as cancer cells. Consequently, the timing of surgical intervention as well
as the specific agents prescribed should be considered in wound healing in patients with
cancer. Several classes of chemotherapeutic agents exist in current treatment protocols, and
each class has characteristic effects on cancer cells and on wound healing as well.
Alkylating agents
Alkylatingagentssuchascyclophosphamide(Cytoxan),chlorambucil(Leukeran),thiotepa
(Thioplex), mechlorethamine (Mustargen), and cisplatin (Platinol) inhibit the cell cycle by
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alkylating DNA nucleotides, leading to cross-linking, strand breakage, and miscoding into
RNA. While their application in different chemotherapeutic regimens is diverse, as a class
these agents typically produce side effects involving the dividing cells of bone marrow, hair
follicles, and gastrointestinal tract; their effects on wound healing are variable. Cyclophos-
phamide, for example, inhibits wound healing by attenuating the initial vasodilation and
subsequent neovascularization during the proliferative phase of wound repair.39−41 Sev-
eral studies in animal models indicate decreased wound tensile strength at doses of 165 to
500 mg/kg.42,43 However, the study by Mann et al did not demonstrate decreased wound
strength at doses less than 100 mg/kg.44 The most deleterious effects on wound ten-
sile strength were seen when 200 mg/kg or higher doses were administered 1 or 2 days
postoperatively.45 Human studies using standard therapeutic doses of 20 to 30 mg/kg did
not result in increased wound complications, however.46,47 Although high-dose cyclophos-
phamide has detrimental effects on wound healing in several animal studies, similar results
in humans at therapeutic doses do not demonstrate this effect; consequently, initiating
cyclophosphamide therapy at therapeutic doses below 100 mg/kg should minimize drug
adverse effects in delaying postsurgical wound healing.
Thiotepa, like cyclophosphamide, inhibits fibroblast function and thus potentially can
delay wound healing. Decreases in wound tensile strength have been demonstrated with
administration of thiotepa at doses of 4 to 8 mg/kg in a rat model48; however, in other trials,
doses of 0.4 mg/kg, 0.6 mg/kg, and 0.8 mg/kg did not result in delayed wound healing.49−51
Similarly, in human studies, therapeutic doses up to 0.8 mg/kg do not seem to impact
wound healing significantly.52,53 These studies also indicate that the timing of thiotepa
administration within the first 3 days of the postoperative period is also not critical, and
therapeutic doses less than 0.8 mg/kg do not result in increased wound complications.1
Mechlorethamine or nitrogen mustard, as it is frequently referred, also negatively
impacts fibroblast function, resulting in delayed wound healing.54,55 In animal studies,
mechlorethamine doses between 0.3 and 0.6 mg/kg decreases wound tensile strength.1 Ad-
ministration of this agent at the time of wounding leads to histologic evidence of impaired
healing, including delayed fibroplasia, delayed endothelial proliferation, and delayed pro-
duction of extracellular fibers, while infusion on the third postoperative day demonstrated
bothadiminishedamountofgranulationtissueandcollagencontent.54,55 However,patients
with breast or colorectal cancers treated with 0.4 mg/kg of mechlorethamine cumulatively
did not demonstrate an increase in wound or anastamotic complications.56 Interestingly,
treating bowel with intraperitoneal mechlorethamine immediately following resection in
patients with colon cancer also did not influence the incidence of wound dehiscence.57
Although animal studies seem to demonstrate detrimental effects of mechlorethamine on
wound healing in the immediate postoperative period, studies in humans have not corrobo-
rated these results.
Aswithmanyoftheotheralkylatingagents,cisplatinhasbeendemonstratedinseveral
animalstudiestosignificantlyimpactwoundhealing.Evenafterasingledoseof5mg/kgin
rats,woundtensilestrengthisreducedwhenassessedonpostoperativedays4,7,14,and28.58
In an investigation by Engelmann et al, preoperative cisplatin in rats decreased fibroblast
proliferation, reduced connective tissue proliferation, and inhibited neovascularization.59
These findings were validated in subsequent studies, which also demonstrated inhibition of
the early proliferative phase of wound healing by cisplatin. In studies involving intestinal
anastamoses, cisplatin-treated rats have a significantly lower anastamotic bursting pressure
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on postoperative days 7–10, although this effect was not clinically significant by postoper-
ative day 14.60,61 The negative effects of cisplatin on wound healing can be attenuated with
concurrenttreatmentwithsodiumthiosulfate,whichlowersplatinumlevelsintissueandhas
demonstrated a protective effect against cisplatin toxicity when the agent is administered
intraperitoneally rather than intravenously.62 Although further testing in human studies is
warranted, experimentally administered cisplatin appears to have detrimental effects on the
early proliferative phase of wound healing, especially with intravenous therapy.
Antimetabolites
Antimetabolites, as a class, function by inhibiting purine and pyrimidine synthesis, which
effectively limits DNA replication as well as RNA transcription. Agents such as methotrex-
ate, 5-fluorouracil, 6-mercaptopurine, and azathioprine (Imuran) are frequent components
of chemotherapeutic regimens for a variety of tumor types. Side effect profiles are char-
acterized by gastrointestinal disturbances, nephrotoxicity, and bone marrow suppression.
Methotrexate, for example, demonstrates a dose-dependent transient decrease in wound
tensilestrengthwhenadministeredpreoperatively.42,54,63 Thiseffectismostpronouncedon
postoperative days 3–7, but tensile strength is equivalent to controls by postoperative day
21.42 Studies in which a leucovorin (folinic acid) “rescue” was administered in conjunction
with methotrexate did not demonstrate an increase in wound complications, although these
studies involved small patient populations that limit the power of the results obtained.64,65
Althoughanimalstudiessuggestarelationshipbetweenthedosingandtimingofmethotrex-
ate administration on postoperative wound healing, a similar effect has yet to be validated
by larger scale human studies. Leucovorin “rescue” in animal studies, however, does seem
to mitigate some of these negative effects on wound tensile strength.63
5-fluorouracil also demonstrates a similar decrease in wound tensile strength in rat
studies when high perioperative doses are administered. This effect is amplified in mal-
nourished rats with 20% to 25% weight loss, which is a dire predictor for patients with
cancer, who tend to be catabolic.66 Several animal studies have attempted to evaluate the
effect of 5-fluorouracil on visceral anastamoses, but these have yielded variable results,
depending on the timing of 5-fluorouracil administration.1,53,67−69 In human subjects ad-
ministered 60 mg/kg of 5-fluorouracil intravenously, contradictory results were obtained
from 2 different studies: 1 study70 demonstrated an increase in wound morbidity when
treatment occurred on postoperative days 7 and 10; the other study did not yield clinically
significant differences when 5-fluorouracil was administered, beginning on postoperative
day 14.71 Although results from animal and human studies are somewhat equivocal, the
potentially negative effect of 5-fluorouracil on wound healing can be minimized when
administered at least 14 days postoperatively in adequately nourished subjects.
The effects of 6-mercaptopurine and azathioprine on wound healing are less clear
than the other antimetabolites. In the case of 6-mercaptopurine, administration of the agent
produces a dose-related suppression of connective tissue organization, a decreased number
of foreign body giant cells, and a derangement in the normal formation of capillaries
in comparison with controls. However, the quantity of macrophages, mononuclear cells,
and fibroblasts were unchanged, as was the amount of hydroxyproline in the extracellular
matrix.72 Unfortunately, as wound tensile strength was not addressed in this study, the
clinical relevance and potential application of these results are inconclusive.1,69 Similarly,
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although azathioprine has been tested in several animal studies, its effects in humans have
not been addressed. In rats, wound healing was transiently suppressed on postoperative day
8, although this effect was negligible by day 15.73 Other studies in which azathioprine was
administered in doses of 20 to 30 mg/kg per day yielded conflicting results in terms of
wound tensile strength.74,75 Further study is warranted before definitive conclusions can be
obtained regarding the effects of these agents on wound healing.
Plant alkaloids
Plant alkaloids such as vincristine (Oncovin) and vinblastine (Velban) affect cell replica-
tion by de-polymerizing microtubule assemblies, effectively halting cell division during
metaphase. These agents typically are associated with a degree of neurotoxicity and hy-
peruricemia, but do not cause significant bone marrow suppression. Studies in mice ad-
ministered 3 mg/kg of vincristine at the time of surgery resulted in a transient decrease
in wound tensile strength on postoperative day 3, which resolves by postoperative days 7
and 21.42 Studies in patients with Wilms’ tumor who were treated with 1.0 to 1.5 mg/m2
of intravenous vincristine preoperatively did not demonstrate an increase in postoperative
wound complications.76 When vincristine was administered in combination with doxoru-
bicin (Adriamycin) and cisplatin preoperatively in sarcoma patients who later underwent
surgical resection, there was no effect on wound morbidity postoperatively.77 Although
a transient decrease in wound healing may occur with vincristine, this does not seem to
increase wound complications in clinical studies.
Antitumor antibiotics
Antitumor antibiotics are another category of agents used in chemotherapeutic regimens in
thetreatmentofmanydifferentformsofcancer.ThesemedicationsinhibitDNA-dependent
RNA synthesis by interfering with transcription. Agents such as bleomycin (Blenoxane),
doxorubicin, actinomycin D, and mitomycin C typically cause gastrointestinal dysfunction
as well as bone marrow toxicity, although each medication also has its own side effect
profile as well. Bleomycin limits skin fibroblast production of collagen, which helps ac-
count for its ability to impede wound healing.78 This effect was noted when 30 mg/kg of
bleomycin administered postoperatively demonstrated decreased wound tensile strength,
most noticeably around postoperative day 7, although similar findings were not evident 3
or 21 days postoperatively.42 This appears to be a dose-dependent and timing-related rela-
tionship, as bleomycin’s negative effects on wound healing also decreased from the time of
administration of the agent.79 Minimal changes are elicited when intralesional bleomycin is
employed, and there is little evidence for morbidity associated with intracavitary bleomycin
as well.80,81 While animal studies suggest that bleomycin may impair wound healing when
dosed preoperatively or at the time of surgery, these effects may not be clinically significant
by 3 weeks postoperatively.
The effects of the antitumor antibiotic doxorubicin on wound healing have been stud-
ied in several animal models. When administered in a single 6 mg/kg perioperative dose
on the day of surgery or 3 days postoperatively, doxorubicin demonstrated a decrease in
wound tensile strength up to 21 days postoperatively in a rat model.42,82 Similar results
were obtained by Mullen et al,83 although the 6 mg/kg dose of doxorubicin utilized in these
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studies was supratherapeutic; therapeutic doses of the agent did not have the same negative
effects.69 Another study utilizing a rabbit model demonstrated a significant decrease in
wound tensile strength 14 days postoperatively when doxorubicin was dosed either 7 or
4 days preoperatively.84 Preoperative administration of this medication has the most pro-
foundeffectonpostoperativewoundhealing,especiallywhendosed7dayspriortosurgery;
postoperatively administered, doxorubicin, however, does not seem to negatively impact
subsequent wound healing.83,85 Lawrence et al demonstrated a decrease in wound tensile
strength only on postoperative days 20 and 30 when 8 mg/kg of doxorubicin was adminis-
tered7dayspostoperativelyinaratmodel.86 Combiningdoxorubicintherapywithradiation
increases the incidence of wound complications, while another study demonstrates a possi-
ble reversal of these effects with the simultaneous administration of growth hormone.85,87
When administered immediately postoperatively or after wound healing has already oc-
curred, doxorubicin treatment did not result in an increase in wound-related complications;
however, administration of the agent should be avoided up to 7 days perioperatively, on the
basis of delayed wound healing seen in animal models.88
Actinomycin D also demonstrates a transient effect on wound healing when studied in
animal models. Postoperative administration of intraperitoneal actinomycin D at 0.6 mg/kg
resulted in a 38% decrease in wound tensile strength on postoperative day 3; however,
this resolves by postoperative day 21.42 Similarly, in rabbits, wound tensile strength is
decreased on postoperative day 7 following topical administration of actinomycin D to
surgically created wounds inoculated with cancer cells.89 While wound healing seems only
transiently impaired by actinomycin D, more evidence exists for the negative effects of
mitomycin C on wounds. When administered intraperitoneally in rats at doses ranging
from 0.23 mg/kg to 0.41 mg/kg, mitomycin C did not affect the wound tensile strength
of intestinal anastamoses; however, 2 mg/kg administered intraperitoneally decreased both
collagen content and wound tensile strength in rats.90−92 Intravesical administration of the
agent in human studies following bladder resection did not demonstrate an increase in
wound complications, although bladder irritation was reported by a minority of patients.93
Mitomycin C, like doxorubicin, can result in soft tissue necrosis and skin ulceration after
extravasation injuries, and animal studies demonstrate that intraperitoneal administration
can delay wound healing in a dose-dependent manner.94
Corticosteroids
Corticosteroids are frequently prescribed for patients with cancer, not as chemotherapeutic
agents but to alleviate pain secondary to tumor growth and the accompanying inflamma-
tory process. Corticosteroid therapy is a well-known impediment to wound healing, both
acutely and following long-term use of this class of medication in the perioperative period
by decreasing the inflammatory response and subsequent fibroplasia.95−100 Preoperative
steroid therapy resulted in a 7.9% incidence of wound dehiscence in Green’s review, with
29% of wounds having some complication of wound healing; other studies have estimated
the incidence of wound dehiscence to be between 0.35% and 3.5% with concurrent steroid
therapy.101 Studies in which corticosteroid therapy was delayed until 3 to 5 days postop-
eratively did not demonstrate a negative effects on wound tensile strength, however.99,102
In addition, coadministration of vitamin A seems to reverse some of the detrimental ef-
fects of steroids on wound healing: topical or systemic vitamin A stimulates monocytic
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inflammation, leading to fibroplasia and subsequent angiogenesis.95,103,104 While preoper-
ative corticosteroid therapy has broad implications on postoperative wound healing over a
widerangeofdosesanddurationoftreatment,delayingtherapyuntilaftertheinflammatory
phase of wound healing has subsided may help minimize these negative effects.
Overall, chemotherapeutic agents have varied effects on tissues, including interfering
withmetabolicprocesses,DNAstructureorreplicationpathways,andcelldivision.Asthese
agents target any rapidly growing tissues in addition to cancer cells, the skin and epithelial
cellsaresusceptibletotheirpotentiallydetrimentaleffectsonwoundhealing.Considerations
such as the cumulative dose and timing of administration during the perioperative period,
the duration of exposure to these agents, and potentially additive effects of combination
therapywithmultipleagentsalsoimpacttheiroverallpotencyandclinicaleffects.Currently,
human studies have not demonstrated significant increases in wound complication rates
from these agents as they are currently administered, either alone or in combination therapy
with radiation and surgery. Delaying the initiation of chemotherapeutic regimens until 7
to 10 days postoperatively seems to have minimal effects on wound healing in this patient
population.
NUTRITION
Although many factors are involved in assessing overall health status in patients with can-
cer, nutrition plays a significant role in influencing tumor biology, comorbid conditions,
and responses to treatment. The relationship between optimal wound healing and positive
nutritional balance is well documented.105 Clinicians must consider their patients’ overall
nutritional status along with any therapeutic interventions being considered, whether that
includessurgery,radiation,chemotherapy,orcombinationsofthesemodalities,tominimize
complications and delays in wound healing in this patient population.
Nutritional status in patients with cancer
In most studies assessing weight loss as the primary indicator of nutritional status in pa-
tients with cancer, approximately 40% to 80% of patients are malnourished, whether this
is due to tumor biology, surgical procedures, radiation or chemotherapy, or psychological
factors.106,107 Malnourished patients have a greater susceptibility to infectious complica-
tions along with delayed wound healing, which, in combination with their diseased state,
significantly increases postoperative morbidity and mortality.108,109 Malnutrition also in-
creases the metabolic activity of organs such as the liver, which physiologically borrows
substrate from skin and muscle to maintain vital functions.108 Maintaining adequate nu-
tritional balance in cancer patients undergoing treatment is essential to minimize the risk
of complications such as enteric fistula formation, incisional wound dehiscence, as well as
carotid rupture after head and neck surgery.105
Physiologicstressorssuchasinfectionandinjuryinitiateaseriesofmetabolicreactions
leadingtoanegativenitrogenbalanceandultimatelyadecreaseinleanbodymass,especially
if patients do not have proper nutritional support. Although the initial metabolic event is
a protective response to injury, if this stage is prolonged for extended periods of time, it
becomes harmful to patients. This stress response, mediated by the complex interaction
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of cytokines, glucocorticoids, catecholamines, insulin, and insulin-like growth factors, can
ultimately lead to a catabolic state if adequate nutritional support is not available.107
Many factors impact nutritional balance in patients with cancer, which can lead to
increased morbidity and mortality during the course of their disease. Malnutrition has
detrimental effects on cellular and humoral immunity in addition to negatively influencing
tissue function and repair. Malnourished cancer patients have less tolerance for therapeutic
interventions than patients in better nutritional states. Also, the tumor burden places in-
creased demands on patients due to stress and tissue injury, which can lead only to further
catabolic responses and nutritional depletion. In this patient population, timely and ade-
quate nutritional supplementation is necessary to minimize the harmful consequences of
malnutrition.107
Patients need adequate supplies of exogenous substrates to meet energy and protein
requirements in order to protect visceral organs and attenuate catabolism of tissues such as
muscle.107 Daily energy expenditure is associated with several components including basal
metabolic rate, thermic effects of exercise, and thermogenic effects from food ingestion.
Stress and illness in critically ill patients can increase basal energy expenditure by up to
40%. Similarly, cancer can induce localized tumor effects from rapid growth and division,
as well as systemic effects due to metastatic disease, both of which can further increase the
metabolic demands on an already critically ill patient. This can lead to glucose intolerance,
increased fat depletion, and increased protein catabolism in these patients, which becomes
more problematic as the tumor burden rises.107
Nutritional management in the critically ill patient
Followingacuteinjury,thebodyundergoes3phasesofrecoveryintermsofmetabolicactiv-
ity:theearlyshockorebbphase,followedbythecatabolicorflowphase,culminatinginthe
anabolic phase.110 Patients in the initial poststress period have an altered chemical environ-
ment characterized by increased levels of glucocorticoids, glucagon, and catecholamines,
along with a decreased level of insulin. This metabolic milieu favors gluconeogenesis,
glycogenolysis, and fatty acid oxidation. Protein derived from muscle is broken down to
supply amino acid substrate for gluconeogenesis.111 This initial poststress state is not fa-
vorable for optimal substrate utilization; in fact, nutritional support is often unsuccessful
during this period, and may even prove detrimental to the patient.112 Consequently, the goal
ofthisphaseisstabilizationofthepatient’scardiopulmonaryandhemodynamicstatus:once
this is achieved and the patient moves into the catabolic phase of recovery, nutritional sup-
port is then indicated. Although the exact timing of initiating enteral or parenteral feeding
has not been entirely determined, it should not be delayed significantly past attainment of
hemodynamic stability.107
Reasonable goals for nutritional support in the critically ill patient include minimiz-
ing starvation effects, preventing specific substrate deficiencies, and supporting the acute
inflammatory response. These issues must be addressed until the hypermetabolic state has
resolved and healing begins. Fluid and electrolyte balance should be attained, and an ade-
quate amount of calories should be provided to meet the increased energy demands of the
patient.Fluidsandelectrolytesmustbejudiciouslyadministeredtomaintainadequateurine
output and normal serum electrolyte levels. Similarly, vitamins and essential dietary ele-
ments must be supplemented according to recommended allowances. Periodic monitoring
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of serum electrolytes, liver enzymes, and lipid levels can ensure appropriate serum lev-
els and helps avoid unnecessary complications.107 Although complete cessation of protein
catabolism and wasting of lean body mass cannot be accomplished, the potential nitro-
gen deficit must be minimized to preserve vital structural proteins from breakdown into
substrates.107
To objectively assess nutritional balance, several laboratory and clinical measures are
available to identify patients at risk of malnourishment. Laboratory assessment of serum al-
bumin,prealbumin,retinol-bindingprotein,andtransferrinlevels;cutaneousanergytesting
of immune responsiveness and total lymphocyte count; and physical determinants like tri-
ceps skin fold measurement and lean body mass may be utilized and followed clinically.113
If these indicators are abnormal prior to surgical intervention, a nutritional support proto-
col is strongly recommended preoperatively to facilitate postoperative wound healing and
minimize wound complications.114 Ultimately, the goal of preoperative support is to allow
adequate protein synthesis postoperatively.115
One difficulty with nutritional support is accurately estimating the energy demands of
the patient to provide adequate substrate to minimize the breakdown of energy stores. A
minimum requirement of 25 to 30 kJ/kg per day is initially recommended for critically ill
patients.116,117 Carbohydratestendtobetheprimarysourceofnonproteincaloriesduringthe
hypermetabolicstateandcancomprise60%to70%ofthedailynutritionalrequirements.In
situations where carbohydrates are either deficient from the diet due to inadequate support
or less available for utilization as in patients with diabetes, protein degradation increases
due to shunting of amino acid carbon skeletons toward gluconeogenesis. Similarly, the
pentose shunt required for synthesis of ribose moieties for basic nucleic acid structure
is also impaired in the context of carbohydrate unavailability, leading to attenuated cell
activation and division.105
Daily fat requirements account for the additional 25% to 30% of nonprotein calo-
ries in hypermetabolic patients.107 Fat provides not only essential dietary fatty acids
but also an energy-rich substrate to help meet metabolic demands. Studies of sepsis
in patients with cancer indicate that calories from fat seem to be a preferred energy
source, even in the presence of ample glucose stores.118−120 Essential fatty acid defi-
ciencyoccurringinmalnutritionlimits18-carbonprecursorsforarachidonicacidsynthesis,
which would negatively impact the inflammatory cascade at wound sites and in infected
tissues.105,121
Similarly,proteinneedsaredramaticallyincreasedincriticallyillpatients.107 Increased
catabolisminthesepatientsisusuallyunresponsivetoproteinorglucoseinfusion;however,
infusion of amino acids induces protein synthesis and allows for restoration of nitrogen
balance.122,123 Studiesinwoundedanimalsdemonstratethatdietsdeficientincertainamino
acids resulted in more pronounced weight loss after injury and delayed healing of wounds.
Essential amino acids including arginine and sulfur-containing amino acids are believed to
be required for optimal wound healing and collagen deposition.124−126 These amino acids
should be provided in adequate amounts to restore the nitrogen balance and limit muscle
breakdown. In general, protein requirements in septic or injured patients range from 1.2
to 2.0 g/kg per /day, depending on the extent of injury and degree of physiologic stress.
Typically,thesuggestednonproteincalorietonitrogenratioisapproximately150:1;inthese
patients,however,higherlevelsofstressrequireincreasedproteinneedsintherangeof80:1
to 100:1.107
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Enteral and parenteral nutritional support
Nutritional supplementation in surgical patients involves enteral or parenteral routes. The
generalruleofthumbforpostoperativenutritionfavorsenteralaccess:“Ifthegutworks,use
it.”107(p751) Enteral feeding is easily administered, well-tolerated, helps maintain the barrier
mechanism of the gastrointestinal tract, and promotes mucosal growth and development.107
In animal studies, enteral feeding also demonstrated an important role in supporting the
body’s mucosal immune defenses.127,128 Enteral nutrition is more efficient, less expensive,
and is associated with fewer metabolic complications like hyperglycemia, cholestasis, and
fatty infiltration of the liver, all of which occur more frequently when the parenteral route is
utilized.129 Several studies in surgical patients also support enteral nutrition if the gastroin-
testinal tract is functional: fewer infectious complications resulted when high-risk surgical
and trauma patients were fed enterally in comparison with parenteral nutrition.107,130,131
Althoughtheenteralrouteispreferredfornutritionalsupport,certainclinicalsituations
require alternate access. In patients who cannot receive enteral support due to mechanical
risks like aspiration or functional deficits such as postoperative ileus, the parenteral route
is an available option. Although total parenteral nutrition (TPN) requires central venous
access through either peripherally or centrally inserted catheters, the risks of line placement
and infection are outweighed by the benefits of adequate nutritional support. Although
randomized, controlled studies have shown little or no benefit of TPN in well-nourished or
slightly malnourished cancer patients undergoing treatments such as surgery, radiation, or
chemotherapy,107 those patients with severe malnutrition prior to therapeutic interventions
demonstrated improved outcomes following major elective surgery, major trauma, and, in
some cases, bone marrow transplantation, when TPN was initiated preoperatively.132,133
Although a precise protocol detailing optimal nutritional therapy in patients with can-
cer does not exist, many attempts have been made to systematically categorize patients by
nutritional status and determine appropriate nutritional support. Not surprisingly, different
subsets of patients respond variably to enteral and parenteral nutrition sources, and clini-
cal studies have been inconclusive regarding routes of administration.107 However, clinical
findings were discussed in a conference sponsored by the National Institutes of Health,
the American Society for Parenteral and Enteral Nutrition, and the American Society for
Clinical Nutrition. Klein et al published the results, in which 33 prospective, randomized,
controlled trials including more than 2500 surgical patients were reviewed to evaluate pe-
rioperative nutritional support. Most patients in this sample population had cancer, the
majority of which were gastrointestinal malignancies. The panel concluded the follow-
ing: (1) TPN administration to malnourished patients—determined by weight loss, plasma
proteins, or prognostic indices—with gastrointestinal cancer 7 to 10 days prior to surgery
reduces postoperative complications by 10%; (2) routine use of early postoperative TPN in
malnourished general surgical patients who did not receive TPN prior to surgery actually
increasespostoperativecomplicationsbyapproximately10%;and(3)postoperativesupport
is mandatory for patients unable to eat for extended periods of time after surgery in order to
prevent the harmful effects of starvation.134 Although the length of time starvation can be
toleratedwithoutasubsequentincreaseinmorbidityisunknown,thepaneldidconcludethat
woundhealingandrecoveryfromsurgerymaybehinderedifTPNadministrationisdelayed
longer than 5 to 10 days postoperatively in patients unable to tolerate enteral feeding.134
Clearly, additional studies are required to further determine the clinical indications for
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parenteral nutrition in the perioperative period, as well as the role of enteral support in the
preoperative period for patients at risk of developing postoperative complications.
Patients with cancer need to obtain nutritional balance to avoid risks associated with
malnutrition and complications of their treatment regimens. Nutritional management of
patients should be incorporated into the overall treatment program but should not interfere
with potentially life-saving or life-extending protocols. Cancer patients requiring surgical
intervention, radiation, and chemotherapy in the management of their diseases clearly can
benefit from improved nutritional and metabolic status to minimize potentially correctable
causes of morbidity and mortality.
Nutritional components for wound healing
In addition to meeting adequate calorie and protein dietary needs in this patient popula-
tion, supplementation of several important vitamins and minerals is also required. These
water-soluble and fat-soluble vitamins function as cofactors in many processes involved in
wound repair and healing.105 Vitamins C and A, along with several other essential com-
ponents, contribute to optimize wound healing and recovery. Vitamin C is necessary for
hydroxylationofprolineandlysineresiduesincollagenpolymerizationandcross-linking.105
Hydroxyproline is essential for the helical stability of collagen and its subsequent secretion
into the extracellular matrix, while hydroxylysine is required for collagen cross-linking and
further polymerization of fibers.2 In the absence of vitamin C, collagen formation is poor,
and the unhydroxylated protein is susceptible to proteolysis.135 This leads to weakness of
the extracellular matrix and the clinical condition scurvy, manifested by abnormal wound
healing.2
Wolfer et al described a 50% reduction in the tensile strength of healing wounds in
patients suffering from vitamin C depletion.136 Similarly, Crandon et al determined that
one third of patients with wound dehiscence postoperatively were deficient in vitamin C.137
DepletionofvitaminC,asmeasuredbyplasmaascorbicacidlevels,interruptsnormalwound
healing due to low tissue levels of ascorbic acid and the resultant decrease in wound tensile
strength; however, normal wound healing can still be achieved if vitamin C is adequately
replaced in the immediate postoperative period.138
Vitamin C also contributes to the body’s resistance to infection.2 In studies performed
by Meyer and Meyer, guinea pigs received subcutaneous injections of Staphylococcus au-
reus, and abscess formation was compared between vitamin C–deficient animals and nond-
eficient animals. In the vitamin C–deficient group, the abscesses formed were much larger
than those in the control group, which was attributed to impaired collagen production in the
test animals, leading to inadequate sequestration or “walling off” of the bacteria.139 Neu-
trophils are also affected in vitamin C deficiency: as vitamin C is required to reduce oxygen
to superoxide, free radical production is decreased and neutrophil function is impaired.2
AlthoughtheroleofvitaminCinwoundhealingiswellrecognized,thereisnoconvinc-
ingevidencethatsupplementingvitaminCwhentissuelevelsarenormalfurtheraccelerates
wound repair and healing. However, it is critical to administer vitamin C in critically ill or
injured patients, as deficiency can rapidly develop because of minimal vitamin C stores
in the body. Patients at risk of developing vitamin C deficiency should receive 1 to2go f
vitamin C daily to optimize wound healing.140
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Vitamin A is another essential cofactor that is elemental in the wound repair pro-
cess. Higher tissue concentrations of vitamin A increases recruitment of macrophages into
wounds, leading to more effective phagocytic activity and cell-mediated immunity.2 Vi-
tamin A has also been demonstrated to reverse some of the anti-inflammatory effects of
corticosteroids, which are frequent components of chemotherapeutic regimens. This may
beattributedtotheabilityofvitaminAtoreversesomeofthestabilizingeffectsofcorticos-
teroidsonlysosomalmembranes,therebyrestoringanactivecomponentoftheinflammatory
response.141,142 Doses of 25,000 IU/oz applied topically to wounds daily have been shown
to have some local benefit without compromising the systemic effects of corticosteroid
therapy.143 Vitamin A deficiency leads to decreased collagen synthesis and cross-linking,
decreased epithelialization, and slower rate of wound closure.144 Patients with severe in-
juries,malabsorption,ormalnutritionareatriskofvitaminAdeficiencyandshouldreceive
dietary supplement of 25,000 IU/day of vitamin A.2
Unlike roles of vitamins C and A, the role vitamin E plays in wound healing is not as
well defined. Structurally, vitamin E is similar to corticosteroids, and functions similarly
to stabilize cell membranes. Although this may implicate vitamin E as being counterpro-
ductive to wound repair, several studies suggest that vitamin E is beneficial to wound
healing.145 For example, rats fed on a vitamin E–deficient diet have impaired collagen syn-
thesis, which implies that vitamin E may be an important cofactor in collagen cross-linking
and polymerization.146 In another investigation, vitamin E was found to have inhibitory ef-
fects on hyaluronidase activity in humans, which suggests a beneficial role in extracellular
matrix deposition.147 Although the contributions of vitamin E are not clearly defined, it is
likely that it contributes toward the wound healing process.
Zinc, an essential cofactor for many enzymes including DNA and RNA polymerase,
serves a variety of biologic functions important for wound healing, including a role in the
biosyntheticpathwayofvitaminA.148−150ZincdeficiencyleadstodecreasedDNAandRNA
synthesis, impaired protein production, and decreased cell proliferation: in zinc-deficient
animals, wound granulation tissue contains lower concentrations of collagen and noncol-
lagenous proteins.2 Restoration of zinc levels to normal has been shown to return wound
healingbacktobaseline.2 AswithvitaminC,zincsupplementationhasnotherapeuticvalue
unless a true zinc deficiency exists; in fact, zinc may be detrimental when present in exces-
sive quantities, as it competitively competes with copper, a cofactor for lysyl oxidase.151,152
This can lead to decreased cross-linking in immature collagen.2 Consequently, it is impor-
tanttorecognizepatientsatriskofdevelopingzincdeficiencyandadministeronlymoderate
amounts of zinc. Patients with malnutrition, infection, severe injuries, malabsorption, or on
long-term TPN should be supplemented with 220 mg of zinc every 8 hours.2
Lawrence et al described an interesting wound healing model in rats inoculated with
106 cells of methylcholanthrene-induced sarcoma either 14 or 7 days prior to wounding
of the skin or deeper structures. The tumor grows locally at the site of administration,
generally does not metastasize, and produces increasingly severe metabolic derangements
beginning approximately 2 weeks after tumor implantation, progressing to death in 5 weeks
after inoculation. Although this study demonstrated an expected impairment in the healing
of incisional wounds, the deeper wounds seemed to heal normally, in spite of a significant
tumorburdenthatmayalterothermetabolicprocesses.Thewoundtensilestrengthbeganto
decrease approximately 19 days after tumor cells were injected, which also corresponded to
theappearanceofothermanifestationsofcancercachexiaaswell:decreasedfoodintakeand
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carcass weight loss, increased gluconeogenesis, and increased whole-body protein turnover
have all been described. It appears that tumor-induced metabolic changes contribute to the
deficiency in wound healing that seems to develop concurrently, implicating a cumulative
effect of tumor biology and host response in impaired wound healing in this model.153
Malnutrition is frequently encountered in patients with cancer and must be addressed
clinically, as protein and calorie deficiencies impact all aspects of their treatment and re-
covery. This subset of patients respond poorly to surgery, with impaired healing of surgical
wounds and anastamoses, leading to the increased incidence of wound and anastamotic
complications.154−156 Consequently, patients must be given adequate nutritional support
in the perioperative period to not only prevent weight loss and correct nitrogen balance
but also support or improve immune function, facilitate tissue repair, and optimize wound
healing.2,157
CONCLUSION
Many factors impede the ability of patients with cancer to heal: the disease process itself,
the timing and invasiveness of the treatments aimed at palliation or cure, and host factors
including mental outlook, nutritional status, and social situation all play important roles
in the management and outcome of their disease. The multimodal approach toward treat-
ing these patients includes a combination of surgical intervention, radiation therapy, and
chemotherapeuticregimens,allofwhichcaninteracttodelaywoundhealinginthispopula-
tion. Consequently, the timing of surgery in relation to radio- and chemotherapy, as well as
the patient’s overall nutritional status, is critical in the recovery from procedures and wound
healing.
Radiotherapyplaysasignificantroleinthelocalcontrolofdisease.However,becauseit
nonspecificallydamagesadjacenttissuesinadditiontocancercells,itcanfurthercomplicate
wound healing. Factors such as the total dose and duration of exposure, the oxygenation
status of the tissue, and the position of cells within the cell cycle influence the cumulative
effects of radiation. Because of radiation-induced injury to the skin, connective tissue,
and underlying vasculature, wound healing is further complicated. Although preoperative
radiation has its indications for reducing tumor burden or making an initially unresectable,
radiosensitive lesion more amenable to surgical excision, the effects on the surrounding
tissue can increase the incidence of wound complications if doses larger than 50 Gy are
administered or if treatments are given less than 3 weeks prior to surgery. As fewer wound
complications have been demonstrated when postoperative radiotherapy is selected, this
treatmentmodalityispreferred.Treatmentcanbedelayedupto6to8weekspostoperatively
to allow the majority of wound healing to occur before initiating radiation therapy.
Chemotherapeuticregimenstargetproliferatingcellsbyinterferingwithspecificcom-
ponents of the cell cycle. Although rapidly dividing tumor cells are the primary target, any
tissues or cell types with high turnover rates—macrophages and fibroblasts involved in
wound healing, for example—are susceptible to the effects of systemic or locally adminis-
tered agents. Consequently, the timing of surgical intervention as well as the specific agents
prescribedshouldbeconsideredwhenmanagingwoundsinpatientswithcancer.Theeffects
of alkylating agents such as cyclophosphamide, thiotepa, mechlorethamine, and cisplatin
have been demonstrated to decrease wound tensile strength and impede wound healing
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during the early proliferative phase in animal studies. However, most human studies at ther-
apeutic doses of these agents have not yielded conclusive results. Similarly, antimetabolites
such as methotrexate, 5-fluorouracil, 6-mercaptopurine, and azathioprine have negative
effects on wound healing when administered during the perioperative period; delaying
treatment with these agents until 2 weeks postoperatively may mitigate some of these ef-
fects. Plant alkaloids such as vincristine transiently decrease wound tensile strength in
animal studies, but this does not appear to be a clinically significant impediment to wound
healing in humans. The antitumor antibiotics, on the other hand, including agents such as
bleomycin, doxorubicin, actinomycin D, and mitomycin C, have variable effects on wound
healing, especially if treatment is initiated perioperatively. Studies on bleomycin and dox-
orubicin demonstrate negative effects on wound tensile strength and collagen synthesis that
canbelimitedbyavoidingtreatmentwithin1weekofsurgicalintervention.Finally,theanti-
inflammatory effects of corticosteroids can be minimized if treatment is held several days
before and after surgery. The concurrent administration of vitamin A reduces some of these
detrimental effects by stimulating monocyte infiltration, fibroplasia, and angiogenesis.
As an estimated 40% to 80% of patients with cancer are clinically malnourished, these
patientsareincreasinglysusceptibletoinfectiouscomplicationsanddelayedwoundhealing.
This is further exacerbated by tumor biology and therapeutic interventions. These patients
require adequate supplies of exogenous substrates to meet energy and protein requirements
and attenuate the catabolism of vital tissues. A minimum requirement of 25 to 30 kJ/kg
per day is recommended for critically ill patients, with carbohydrates comprising 60% to
70% of nonprotein calories and the remainder supplied by dietary fats, including 18-carbon
precursors necessary for arachidonic acid synthesis. Protein requirements between 1.2 and
2.0 g/kg per day are also required, and should include essential amino acids such as argi-
nine and methionine, both of which are necessary for optimal wound healing. The choice
between enteral and parenteral nutrition is usually made on the basis of clinical indications;
however, when possible, enteral supplementation is preferred, as studies have demonstrated
fewer metabolic and infectious complications with enteral nutrition. Finally, deficiencies in
antioxidants such as vitamins C and A, vitamin E, and zinc, all of which function as cofac-
tors in the wound healing process, should be corrected with supplementation, as clinically
indicated.
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